Proteolytic Matrix Metallopeptidases and Inhibitors in BCR-ABL1-Negative Myeloproliferative Neoplasms: Correlation with JAK2V617F Mutation Status

Publisher： Karger

E-ISSN： 1421-9662|126|1|54-62

ISSN： 0001-5792

Source： Acta Haematologica, Vol.126, Iss.1, 2011-04, pp. : 54-62

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Coexistence of JAK2V617F Mutation and BCR-ABL1 Transcript in Two Chinese Patients with Chronic Myelogenous Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 1, 2011-10 ,pp. : 47-49

Karger

Access to resources Recommend Favorite

Leukocytosis, JAK2V617F Mutation, and Hemostasis in Myeloproliferative Disorders

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 36, Iss. 3-4, 2009-01 ,pp. : 148-159

Karger

Access to resources Recommend Favorite

Evaluation of JAK2V617F in B and T Cell Neoplasms: Identification of JAK2V617F Mutation of Undetermined Significance (JMUS) in the Bone Marrow of Three Individuals

By  

Acta Haematologica, Vol. 118, Iss. 4, 2007-11 ,pp. : 209-214

Karger

Access to resources Recommend Favorite

Is the JAK2 V617F Mutation a Hallmark for Different Forms of Thrombosis?

By  

Acta Haematologica, Vol. 124, Iss. 1, 2010-07 ,pp. : 49-56

Karger

Access to resources Recommend Favorite

Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines

By  

Acta Haematologica, Vol. 132, Iss. 1, 2014-01 ,pp. : 75-86

Karger

Access to resources Recommend Favorite